Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: Developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV

Abstract

Latent HIV can be activated through inhibition of histone deacetylase using HDAC inhibitors (HDACi). Pleiotropic effects of HDAC include reactivation of other latent viruses. To minimize such risks, we have developed a novel PLGA immuno-nanoparticle for delivering HDACi exclusively to human T cells, the major reservoirs for latent HIV, using a single chain fragment antibody targeting the CD7 molecule on T cells. The immuno-nanoparticle successfully activated latent HIV in the human T cell line ACH2 and could deliver cargo to primary human T cells. This approach opens avenues for the eradication of HIV when used with HAART through elimination of HIV reservoirs.